Literature DB >> 23110560

Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.

Theodoros Kalampokas1, George Creatsas, Emmanouil Kalampokas.   

Abstract

One of the most serious complications of assisted reproduction techniques is ovarian hyperstimulation syndrome (OHSS). OHSS not only increases morbidity and mortality in IFV cycles, but also causes significant other problems, as cancelled in vitro fertilization (IVF) cycles, prolonged hospitalization, causing emotional and sociofinancial consequences. Several treatments for OHSS have been proposed and among these Cabergoline (Cb2). Despite the above-mentioned beneficial effect, Cb2 has not been widely used in everyday's clinical practice. With our study, we try to review all studies with strong evidence examining Cb2 use for OHSS prevention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23110560     DOI: 10.3109/09513590.2012.730578

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

Review 1.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma Mourad; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

Review 2.  Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.

Authors:  Selma Mourad; Julie Brown; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2017-01-23

3.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma M Mourad; Aihua Wang; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

4.  Management of ovarian hyperstimulation syndrome with abdominal compartment syndrome, based on intravesical pressure measurement.

Authors:  Hiroshi Makino; Tatsuro Furui; Tomomi Shiga; Motoki Takenaka; Keiko Terazawa; Ken-Ichiro Morishige
Journal:  Reprod Med Biol       Date:  2016-11-30

5.  Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity.

Authors:  Haruki Odaka; Tadahiro Numakawa; Naoki Adachi; Yoshiko Ooshima; Shingo Nakajima; Yusuke Katanuma; Takafumi Inoue; Hiroshi Kunugi
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

6.  Predictive factors for recovery time in patients suffering from severe OHSS.

Authors:  Kazem Nouri; Clemens B Tempfer; Christian Lenart; Lisa Windischbauer; Katharina Walch; Regina Promberger; Johannes Ott
Journal:  Reprod Biol Endocrinol       Date:  2014-07-05       Impact factor: 5.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.